Last reviewed · How we verify
%40 diluted Autologous serum
Diluted autologous serum provides immunomodulatory and anti-inflammatory effects through patient-derived serum factors.
Diluted autologous serum provides immunomodulatory and anti-inflammatory effects through patient-derived serum factors. Used for Dry eye syndrome, Ocular surface disease, Corneal ulceration.
At a glance
| Generic name | %40 diluted Autologous serum |
|---|---|
| Sponsor | Niğde State Hospital |
| Drug class | Autologous biologic |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Autologous serum therapy uses a patient's own blood serum, typically diluted to 40% concentration, to deliver endogenous immunoglobulins, cytokines, and growth factors that modulate local immune responses and reduce inflammation. The mechanism is thought to involve both specific and non-specific immune regulation, promoting tissue healing and reducing pathological inflammation at the site of application.
Approved indications
- Dry eye syndrome
- Ocular surface disease
- Corneal ulceration
Common side effects
- Local irritation
- Infection risk
- Allergic reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- %40 diluted Autologous serum CI brief — competitive landscape report
- %40 diluted Autologous serum updates RSS · CI watch RSS
- Niğde State Hospital portfolio CI